IDS and mucopolysaccharidosis type 2: Intravenous enzyme replacement therapy (ERT) with recombinant idursulfase (Elaprase, Takeda Pharmaceuticals USA., Inc., Lexington, MA, USA) has been available since 2006 and is the recommended treatment for MPS II [9,12,13,14].